Patents by Inventor Katrin Groebke Zbinden
Katrin Groebke Zbinden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220411415Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: July 16, 2021Publication date: December 29, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Bernd BUETTELMANN, Giuseppe Cecere, Bernhard Fasching, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Emmanuel Pinard, Andrew Thomas
-
Publication number: 20220135591Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein R1 to R7, A, L1, and RA1 to RA3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: October 8, 2021Publication date: May 5, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Guillaume DECORET, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Bernd KUHN, Hans RICHTER, Didier ROMBACH, Fionn O'HARA, Carsten KROLL
-
Publication number: 20210387999Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, X, R1, R2, R3 and R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: May 20, 2021Publication date: December 16, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Bernd KUHN, Uwe GRETHER, Benoit HORNSPERGER, Hans RICHTER, Carsten KROLL, Katrin GROEBKE ZBINDEN, Fionn O'HARA, Didier ROMBACH, Marius Daniel Rinaldo LUTZ
-
Publication number: 20210277020Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using the compounds and methods of determining the monoacylglycerol lipase (MAGL) inhibitory activity of the compounds.Type: ApplicationFiled: February 11, 2021Publication date: September 9, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Lilli ANSELM, Joerg BENZ, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Dominik HEER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Fionn O`HARA, Hans RICHTER
-
Patent number: 11091471Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: June 5, 2019Date of Patent: August 17, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Buettelmann, Giuseppe Cecere, Bernhard Fasching, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Emmanuel Pinard, Andrew Thomas
-
Publication number: 20210107920Abstract: The invention provides new heterocyclic compounds having the general formula (Ic) wherein A, L, X, m, n and R20 to R23 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 18, 2020Publication date: April 15, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Dennis Jul HANSEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Fionn O'HARA, Hans RICHTER, Martin RITTER, Satoshi TSUCHIYA, Rui CHEN
-
Publication number: 20210094945Abstract: The invention provides novel compounds having the general formula (I) or (II) wherein R2, R3, R5, R99, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 11, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Giuseppe Cecere, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Andres Miguel Olivares Morales, Angélique Patiny-Adam, Emmanuel Pinard, Valerie Runtz-Schmitt, Sandra Steiner
-
Publication number: 20210094973Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L1, X, m, n and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 22, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER
-
Publication number: 20210094943Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and RI to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: September 10, 2020Publication date: April 1, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
-
Publication number: 20210061760Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.Type: ApplicationFiled: November 12, 2020Publication date: March 4, 2021Inventors: Katrin Groebke Zbinden, Roger Norcross, Phillippe Pfileger
-
Publication number: 20200308190Abstract: The invention provides new heterocyclic compounds having the general formula wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.Type: ApplicationFiled: April 9, 2020Publication date: October 1, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER, Didier ROMBACH, Martin KURATLI
-
Publication number: 20200048194Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.Type: ApplicationFiled: October 15, 2019Publication date: February 13, 2020Inventors: Katrin Groebke Zbinden, Roger Norcross, Phillippe Pfileger
-
Patent number: 10501411Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.Type: GrantFiled: May 18, 2016Date of Patent: December 10, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Katrin Groebke Zbinden, Roger Norcross, Philippe Pflieger
-
Publication number: 20190300516Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: June 5, 2019Publication date: October 3, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Bernd BUETTELMANN, Giuseppe CECERE, Bernhard FASCHING, Katrin GROEBKE ZBINDEN, Maria-Clemencia HERNANDEZ, Henner KNUST, Andreas KOBLET, Emmanuel PINARD, Andrew THOMAS
-
Patent number: 10399985Abstract: The present invention relates to compounds of formula I, wherein A, B, R1, R2, and Z are as defined hereinbefore.Type: GrantFiled: July 27, 2016Date of Patent: September 3, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Flohr, Katrin Groebke Zbinden
-
Patent number: 9932335Abstract: The present invention relates to compounds of formula wherein R1, Y1, Y2, X, R and n are as defined herein.Type: GrantFiled: March 11, 2016Date of Patent: April 3, 2018Assignee: HOFFMANN-LA ROCHE INC.Inventors: Theresa Maria Ballard, Emmanuel Pinard, Herve Schaffhauser, Katrin Groebke Zbinden, Thomas Ryckmans, Alexander Flohr
-
Patent number: 9708259Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable addition salts, racemic mixtures or the corresponding enantiomers and optical isomers thereof. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain and sleep disorder.Type: GrantFiled: March 28, 2016Date of Patent: July 18, 2017Assignee: HOFFMANN-LA ROCHE INC.Inventors: Theresa M. Ballard, Katrin Groebke Zbinden, Emmanuel Pinard, Thomas Ryckmans, Herve Schaffhauser, Jean-Baptiste Blanc
-
Patent number: 9708302Abstract: The present invention relates to compounds of formula wherein R1 is C4-6-cycloalkyl or C4-6-heterocycloalkyl, which are optionally substituted by one or two substituents, selected from hydroxy or lower alkyl; A is phenyl, pyridinyl or piperidinyl; R2 is hydrogen, halogen, lower alkyl, cyano, C4-6-cycloalkyl, lower alkoxy, lower alkoxy substituted by halogen, or is a five- or six-membered heteroaryl, optionally substituted by lower alkyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.Type: GrantFiled: July 21, 2016Date of Patent: July 18, 2017Assignee: HOFFMANN-LA-ROCHE INC.Inventors: Katrin Groebke Zbinden, Emmanuel Pinard, Thomas Ryckmans
-
Patent number: 9617271Abstract: The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.Type: GrantFiled: May 6, 2015Date of Patent: April 11, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Alexander Flohr, Katrin Groebke Zbinden, Christian Lerner
-
Patent number: 9540384Abstract: The invention relates to compounds of formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.Type: GrantFiled: November 26, 2014Date of Patent: January 10, 2017Assignee: Hoffmann-La Roche, Inc.Inventors: Alexander Flohr, Katrin Groebke Zbinden, Matthias Koerner, Christian Lerner